Arcadia Biosciences, Inc., an agricultural food ingredient company, develops and commercializes health and nutrition ingredient traits worldwide. The company offers a suite of agricultural productivity traits, including nitrogen use efficiency, water use efficiency and drought tolerance, salinity tolerance, and herbicide tolerance traits. It also provides nutritional oils comprising gamma linolenic acid safflower oil to manufacturers of dietary and nutritional supplements, medical foods, dog food, and other products under the SONOVA brand; and arachidonic acid safflower oil that is used as an ingredient in infant nutrition products. In addition, the company has various programs under development comprising fiber resistant starch wheat, whole grain flour, and reduced gluten wheat programs. Arcadia Biosciences, Inc. has strategic collaborations with Dow AgroSciences and Ardent Mills LLC to develop and commercialize wheat varieties. The company was founded in 2002 and is headquartered in Davis, California.
Industry, Sector and Symbol
Industry Agricultural chemicals
Sub-IndustryN/A
SectorBasic Materials
Phone530-756-7077
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.46 million
Profitability
Miscellaneous
Employees44
Next Earnings Date8/14/2019 (Estimated)
OptionableNot Optionable
Arcadia Biosciences (NASDAQ:RKDA) Frequently Asked Questions
What is Arcadia Biosciences' stock symbol?
Arcadia Biosciences trades on the NASDAQ under the ticker symbol "RKDA."
When did Arcadia Biosciences' stock split? How did Arcadia Biosciences' stock split work?
Arcadia Biosciences shares reverse split on Wednesday, January 24th 2018. The 1-20 reverse split was announced on Tuesday, January 23rd 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 23rd 2018. An investor that had 100 shares of Arcadia Biosciences stock prior to the reverse split would have 5 shares after the split.
How were Arcadia Biosciences' earnings last quarter?
Arcadia Biosciences Inc (NASDAQ:RKDA) released its quarterly earnings results on Wednesday, May, 8th. The basic materials company reported ($1.24) EPS for the quarter, missing the consensus estimate of ($0.61) by $0.63. The basic materials company earned $0.16 million during the quarter, compared to analyst estimates of $0.40 million. Arcadia Biosciences had a negative return on equity of 178.78% and a negative net margin of 1,099.22%. View Arcadia Biosciences' Earnings History.
When is Arcadia Biosciences' next earnings date?
What price target have analysts set for RKDA?
2 analysts have issued 12-month target prices for Arcadia Biosciences' stock. Their predictions range from $15.00 to $20.00. On average, they expect Arcadia Biosciences' stock price to reach $17.50 in the next year. This suggests a possible upside of 239.8% from the stock's current price. View Analyst Price Targets for Arcadia Biosciences.
What is the consensus analysts' recommendation for Arcadia Biosciences?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcadia Biosciences in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arcadia Biosciences.
What are Wall Street analysts saying about Arcadia Biosciences stock?
Here are some recent quotes from research analysts about Arcadia Biosciences stock:
- 1. National Securities analysts commented, " First Quarter Operating Results Narrowly Beat Estimates. An operating loss of $4.2 million narrowly beat our estimate of $4.8 million, while a cash burn of $4.0 million met our estimates. A GAAP loss of $2.64 per share was skewed by an $8.4 million non-cash adjustment to the fair value of warrant liabilities. Excluding this, losses would have come in at $0.89 per share, better than our estimate of $1.01 per share.
GoodWheat Commercialization On Track. Seed bulk up in advance of commercialization of the Resistant Starch variety has taken place, and growers are in line for the upcoming planting season in several states. Supply chain development and discussions with potential milling and consumer goods companies are advancing, and initial revenue is expected by the fourth quarter of 2019.
Cannabis Initiative Rapidly Progressing. Initial hemp plantings in Hawaii are set to harvest in the summer, and additional plantings are expected on an ongoing basis. Of note is that management expects to be able to announce cannabis partnerships in coming months, which we believe could represent a near term catalyst for the stock.
Next Twelve Months Could Be Transformative. Between the initial revenues of the two lead products and the rapid progression of cannabis breeding initiatives, we believe the company is effectively positioned to evolve from a pre-commercial revenue business into a meaningful value creator over the next twelve months." (5/9/2019)
- 2. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. Our valuation utilizes a discounted cash flow-based approach that derives a $140M value for RS Wheat, using a 15% discount rate, 30% tax rate and 10% manufacturing spend." (2/28/2019)
- 3. According to Zacks Investment Research, "Arcadia Biosciences, Inc. is engaged in developing and commercializing agricultural products primarily in the United States. The Company's product includes nitrogen use crops, salt tolerant plants, sunflower oil and shelf-life produce. Arcadia Biosciences, Inc. is headquartered in Davis, California. " (2/14/2019)
Has Arcadia Biosciences been receiving favorable news coverage?
Headlines about RKDA stock have trended negative on Wednesday, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Arcadia Biosciences earned a daily sentiment score of -2.0 on InfoTrie's scale. They also gave headlines about the basic materials company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the near term.
Who are some of Arcadia Biosciences' key competitors?
What other stocks do shareholders of Arcadia Biosciences own?
Who are Arcadia Biosciences' key executives?
Arcadia Biosciences' management team includes the folowing people:
- Mr. Rajendra Ketkar, Pres, CEO & Director (Age 65)
- Mr. Matthew T. Plavan, CFO, Sec. & Pres of Arcadia Specialty Genomics (Age 55)
- Ms. Sarah Reiter, Chief Commercial Officer (Age 47)
- Dr. Randy Shultz Ph.D., Head of R&D
- Dr. Zhongjin Lu Ph.D., Director of Product Devel. (Age 53)
When did Arcadia Biosciences IPO?
(RKDA) raised $66 million in an initial public offering on Friday, May 15th 2015. The company issued 8,200,000 shares at a price of $8.00 per share. Credit Suisse, J.P. Morgan and Piper Jaffray acted as the underwriters for the IPO.
Who are Arcadia Biosciences' major shareholders?
Arcadia Biosciences' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Virtu Financial LLC (0.29%). Company insiders that own Arcadia Biosciences stock include Eric J Rey and Zhongjin Lu. View Institutional Ownership Trends for Arcadia Biosciences.
Which institutional investors are selling Arcadia Biosciences stock?
How do I buy shares of Arcadia Biosciences?
Shares of RKDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Arcadia Biosciences' stock price today?
One share of RKDA stock can currently be purchased for approximately $5.15.
How big of a company is Arcadia Biosciences?
Arcadia Biosciences has a market capitalization of $24.60 million and generates $1.46 million in revenue each year. The basic materials company earns $-13,480,000.00 in net income (profit) each year or ($5.35) on an earnings per share basis. Arcadia Biosciences employs 44 workers across the globe.
What is Arcadia Biosciences' official website?
How can I contact Arcadia Biosciences?
Arcadia Biosciences' mailing address is 202 COUSTEAU PLACE SUITE 105, DAVIS CA, 85018. The basic materials company can be reached via phone at 530-756-7077 or via email at [email protected]
MarketBeat Community Rating for Arcadia Biosciences (NASDAQ RKDA)
MarketBeat's community ratings are surveys of what our community members think about Arcadia Biosciences and other stocks. Vote "Outperform" if you believe RKDA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RKDA will underperform the S&P 500 over the long term. You may vote once every thirty days.
